Innate Pharma Stock Performance
| IPHA Stock | USD 1.69 0.11 6.11% |
The company retains a Market Volatility (i.e., Beta) of 1.28, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Innate Pharma will likely underperform. At this point, Innate Pharma has a negative expected return of -0.27%. Please make sure to check out Innate Pharma's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Innate Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Innate Pharma co-organise un symposium scientifique en prsence dexperts de lImmunotherapie New York le 3 octobre 2024 | 09/30/2024 |
2 | Jonathan Dickinson est nomm Prsident du Directoire dInnate Pharma | 10/14/2024 |
3 | Innate Pharma organise une confrence tlphonique pour ses rsultats financiers et lavance de son portefeuille au troisime trimestre 2024 | 11/07/2024 |
4 | Innate Pharma Q3 2024 Update New Leadership, FDA Progress, and Strong Cash Position | 11/13/2024 |
5 | Innate Pharma annonce une publication dans la revue Science Immunology mettant en avant le NK cell engager ANKET de nouvelle gnration IPH6501 | 11/19/2024 |
6 | Innate Pharma publie son calendrier financier pour 2025 | 11/20/2024 |
7 | Innate Pharma et lInstitut dInnovation pour le Lymphome Folliculaire annoncent un investissement jusqu 7,9 millions de dollars de lIFLI pour soutenir le dvelopp... | 12/06/2024 |
8 | Innate Pharma prsente lASH 2024 des donnes de ltude de Phase 2 TELLOMAK sur lamlioration de la qualit de vie chez des patients atteints de lymphomes T cutans | 12/09/2024 |
| Begin Period Cash Flow | 84.2 M |
Innate |
Innate Pharma Relative Risk vs. Return Landscape
If you would invest 226.00 in Innate Pharma on September 13, 2024 and sell it today you would lose (57.00) from holding Innate Pharma or give up 25.22% of portfolio value over 90 days. Innate Pharma is currently does not generate positive expected returns and assumes 6.3553% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Innate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Innate Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innate Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Innate Pharma, and traders can use it to determine the average amount a Innate Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0428
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IPHA |
Estimated Market Risk
| 6.36 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Innate Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innate Pharma by adding Innate Pharma to a well-diversified portfolio.
Innate Pharma Fundamentals Growth
Innate Stock prices reflect investors' perceptions of the future prospects and financial health of Innate Pharma, and Innate Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innate Stock performance.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (1.01) % | ||||
| Operating Margin | (2.13) % | ||||
| Current Valuation | 85.13 M | ||||
| Shares Outstanding | 80.95 M | ||||
| Price To Book | 4.51 X | ||||
| Price To Sales | 4.28 X | ||||
| Revenue | 51.9 M | ||||
| Gross Profit | 57.67 M | ||||
| EBITDA | (1.84 M) | ||||
| Net Income | (7.57 M) | ||||
| Cash And Equivalents | 123.35 M | ||||
| Cash Per Share | 1.54 X | ||||
| Total Debt | 39.89 M | ||||
| Debt To Equity | 0.37 % | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | 0.36 X | ||||
| Cash Flow From Operations | (32.56 M) | ||||
| Earnings Per Share | (0.44) X | ||||
| Market Capitalization | 144.73 M | ||||
| Total Asset | 184.19 M | ||||
| Retained Earnings | (336.89 M) | ||||
| Working Capital | 108.38 M | ||||
About Innate Pharma Performance
By analyzing Innate Pharma's fundamental ratios, stakeholders can gain valuable insights into Innate Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Innate Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Innate Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (0.02) | (0.02) | |
| Return On Tangible Assets | (0.04) | (0.04) | |
| Return On Capital Employed | (0.09) | (0.09) | |
| Return On Assets | (0.04) | (0.04) | |
| Return On Equity | (0.15) | (0.15) |
Things to note about Innate Pharma performance evaluation
Checking the ongoing alerts about Innate Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Innate Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innate Pharma generated a negative expected return over the last 90 days | |
| Innate Pharma has high historical volatility and very poor performance | |
| Innate Pharma may become a speculative penny stock | |
| Innate Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 51.9 M. Net Loss for the year was (7.57 M) with profit before overhead, payroll, taxes, and interest of 57.67 M. | |
| Innate Pharma currently holds about 123.35 M in cash with (32.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.54. | |
| Innate Pharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from businesswire.com: Innate Pharma prsente lASH 2024 des donnes de ltude de Phase 2 TELLOMAK sur lamlioration de la qualit de vie chez des patients atteints de lymphomes T cutans |
- Analyzing Innate Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innate Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Innate Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innate Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innate Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Innate Pharma's stock. These opinions can provide insight into Innate Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |